Financial Survey: Ekso Bionics Holdings (EKSO) & Strata Skin Sciences (SSKN)
Ekso Bionics Holdings (NASDAQ: EKSO) and Strata Skin Sciences (NASDAQ:SSKN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.
Risk & Volatility
Ekso Bionics Holdings has a beta of -0.86, meaning that its stock price is 186% less volatile than the S&P 500. Comparatively, Strata Skin Sciences has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.
Valuation & Earnings
This table compares Ekso Bionics Holdings and Strata Skin Sciences’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Ekso Bionics Holdings||$7.49 million||4.30||-$27.14 million||($1.55)||-0.81|
|Strata Skin Sciences||$32.37 million||0.13||$5.87 million||($2.70)||-0.64|
Strata Skin Sciences has higher revenue and earnings than Ekso Bionics Holdings. Ekso Bionics Holdings is trading at a lower price-to-earnings ratio than Strata Skin Sciences, indicating that it is currently the more affordable of the two stocks.
This table compares Ekso Bionics Holdings and Strata Skin Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ekso Bionics Holdings||-372.20%||-798.93%||-146.30%|
|Strata Skin Sciences||-18.00%||-41.58%||-13.22%|
Insider and Institutional Ownership
6.0% of Ekso Bionics Holdings shares are owned by institutional investors. Comparatively, 24.1% of Strata Skin Sciences shares are owned by institutional investors. 7.1% of Ekso Bionics Holdings shares are owned by insiders. Comparatively, 12.9% of Strata Skin Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a summary of current ratings and price targets for Ekso Bionics Holdings and Strata Skin Sciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ekso Bionics Holdings||0||0||2||0||3.00|
|Strata Skin Sciences||0||0||2||0||3.00|
Ekso Bionics Holdings currently has a consensus price target of $6.00, indicating a potential upside of 380.00%. Strata Skin Sciences has a consensus price target of $12.00, indicating a potential upside of 597.67%. Given Strata Skin Sciences’ higher possible upside, analysts clearly believe Strata Skin Sciences is more favorable than Ekso Bionics Holdings.
Strata Skin Sciences beats Ekso Bionics Holdings on 9 of the 11 factors compared between the two stocks.
Ekso Bionics Holdings Company Profile
Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness. The companys Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exoskeletons and related technologies. The company has a license agreement with Lockheed Martin Corporation to develop products for military applications, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California. Ekso Bionics Holdings, Inc. operates as a subsidiary of Magee Rehabilitation Hospital.
Strata Skin Sciences Company Profile
STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company’s technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment.
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.